Search

Your search keyword '"Ziske, Carsten"' showing total 154 results

Search Constraints

Start Over You searched for: Author "Ziske, Carsten" Remove constraint Author: "Ziske, Carsten"
154 results on '"Ziske, Carsten"'

Search Results

1. Primary small cell carcinoma of the esophagus: patient data metaanalysis and review of the literature [Primäres kleinzelliges Ösophaguskarzinom: Patientendaten-Metaanalyse und Review der Literatur ]

2. High-dose chemotherapy with autologous peripheral blood stem cell support for recurrent primary AFP-producing intracranial germinoma

3. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

4. Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

5. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

6. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial

7. Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

8. Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

10. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

11. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

22. Post-Authorization Safety Study of Lenalidomide-Based vs Non–Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

24. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial

25. Uses of error : Partial splenectomy

26. Clostridium difficile Infection in Patients with Neutropenia

27. T-Rex study: Quality of life assessment using novel CTCAE-PRO and FKSI-19 in first-line treatment of metastatic renal cell carcinoma with tivozanib.

29. Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2nd-Line Therapy for Multiple Myeloma

30. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial.

31. Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids

42. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer

44. Clostridium difficileInfection in Patients with Neutropenia

45. A Novel Minimal-Size Vector (MIDGE) Improves Transgene Expression in Colon Carcinoma Cells and Avoids Transfection of Undesired DNA

47. Resistance of Pancreatic Carcinoma Cells Is Reversed by Coculturing NK-like T Cells with Dendritic Cells Pulsed with Tumor-Derived RNA and CA 19-9

48. Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients

Catalog

Books, media, physical & digital resources